Precision Medicine and/or Biomarker Based Therapy in T2DM: Ready for Prime Time?
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
Precision Medicine and/or Biomarker Based Therapy in T2DM : Ready for Prime Time? / Rossing, Peter; Frimodt-Møller, Marie; Persson, Frederik.
I: Seminars in Nephrology, Bind 43, Nr. 3, 151430, 2023.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Precision Medicine and/or Biomarker Based Therapy in T2DM
T2 - Ready for Prime Time?
AU - Rossing, Peter
AU - Frimodt-Møller, Marie
AU - Persson, Frederik
N1 - Copyright © 2023 Elsevier Inc. All rights reserved.
PY - 2023
Y1 - 2023
N2 - Approximately 30-40% of people with type 2 diabetes mellitus develop chronic kidney disease. This is characterised by elevated blood pressure, declining kidney function and enhanced cardiovascular morbidity and mortality. Increased albuminuria and decreasing estimated glomerular function has to be evaluated regularly to diagsnose kidney disease. New biomarkers may facilitate early diagnosis and provide infomation on undlying pathology thereby supporting early precision intervention for the optimal benefit. A number of biomarkers have been suggested but are not yet implemented in clinical practice. iI the future such bimarkers may pave the way for personalized treatment.
AB - Approximately 30-40% of people with type 2 diabetes mellitus develop chronic kidney disease. This is characterised by elevated blood pressure, declining kidney function and enhanced cardiovascular morbidity and mortality. Increased albuminuria and decreasing estimated glomerular function has to be evaluated regularly to diagsnose kidney disease. New biomarkers may facilitate early diagnosis and provide infomation on undlying pathology thereby supporting early precision intervention for the optimal benefit. A number of biomarkers have been suggested but are not yet implemented in clinical practice. iI the future such bimarkers may pave the way for personalized treatment.
KW - Humans
KW - Diabetes Mellitus, Type 2/drug therapy
KW - Precision Medicine
KW - Renal Insufficiency, Chronic/diagnosis
KW - Hypertension
KW - Biomarkers
KW - Albuminuria/diagnosis
KW - Glomerular Filtration Rate
KW - Diabetic Nephropathies/diagnosis
U2 - 10.1016/j.semnephrol.2023.151430
DO - 10.1016/j.semnephrol.2023.151430
M3 - Review
C2 - 37862744
VL - 43
JO - Seminars in Nephrology
JF - Seminars in Nephrology
SN - 0270-9295
IS - 3
M1 - 151430
ER -
ID: 381063649